Inflazyme Pharmaceuticals Ltd.

Inflazyme Pharmaceuticals Ltd.

August 30, 2007 21:00 ET

Inflazyme Pharmaceuticals Announces a Revised Date for its AGM

VANCOUVER, BRITISH COLUMBIA--(Marketwire - Aug. 30, 2007) - Inflazyme Pharmaceuticals Ltd. (TSX:IZP) today announced that it had received approval from the TSX to extend the date of its Annual General Meeting (AGM). Inflazyme will now hold its AGM combined with a Special Meeting on October 25, 2007. The new record date is September 20, 2007. Further information on the meeting will be provided in due course.

The Company had previously announced that it was holding its AGM and Special Meeting on September 27, 2007 with the record date as August 22, 2007. These dates are no longer applicable. The date was changed because the Company may have a matter that requires shareholder approval and for cost purposes it does not wish to hold a second meeting.

About Inflazyme

Inflazyme Pharmaceuticals is a biopharmaceutical company pioneering medical breakthroughs to transform the lives of patients with respiratory and inflammatory diseases worldwide. Further information on the Company may be obtained from its website at

This news release contains certain "forward-looking statements" and "forward-looking information" which may include but is not limited to statements in respect of our future financial position or operations. Words like "believe", "intend", "may", "expect", "anticipate", "plan", "should" and other similar expressions are forward-looking statements that involve a number of risks and uncertainties. By their nature, forward-looking statements involve numerous factors, assumptions and estimates, some but not all of the factors that could cause actual results to differ materially from those projected in our forward-looking statements include among others: risks associated with the completion of clinical trials and obtaining regulatory approval to market our products, market acceptance of our technologies and products; our ability to obtain financing; our financial and technical resources relative to those of our competitors; our ability to enforce our intellectual property rights and protect our proprietary technologies; the ability to obtain and develop partnership opportunities; and other risk factors identified from time to time in the Company's regulatory filings. For a further description of the principal risks affecting the Company, see our regulatory filings. These factors should be considered carefully and readers are cautioned not to place undue reliance on such forward-looking statements. The Company disclaims any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements.

Contact Information

  • Inflazyme Pharmaceuticals Ltd.
    Julie Rezler
    Sr. Director, Corporate Development
    1-800-315-3660 or (604) 279-8511
    (604) 279-8711 (FAX)